EGFR and glioblastoma: Previously, we generated a bivalent recombinant immunotoxin, hDT806, targeting EGFRvIII and overexpressed EGFR in cancers and demonstrated its high potency against glioblastoma cells with EGFR and EGFRvIII overexpression [15].